Since S100A7 content is elevated in the CSF of AD dementia cases compared to neurological control cases, and these elevated S100A7 levels in the CSF selectively identify AD clinical severity, S100A7 could be a biomarker that quickly diagnoses AD before clinical signs have developed, allowing for early symptomatic treatment and the ability to chart the course of the disease accurately. Here, S100A7 is linked to Alzheimer disease.